Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY (LLY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 02:01pm CEST

(Reuters) - Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
03:15pELI LILLY AND CO : quaterly earnings release
11:15aELI LILLY AND : Boehringer Ingelheim and Lilly announce an academic collaboratio..
AQ
04/16ELI LILLY AND : Health and Human Services Department (HHS); Food and Drug Admini..
AQ
04/16ELI LILLY AND : Boehringer Ingelheim and Lilly announce an academic collaboratio..
PR
04/12ELI LILLY AND : Trademark Application for "CONQUER" Filed by Eli Lilly
AQ
04/12ELI LILLY AND : New Organic Research Study Findings Reported from Eli Lilly and ..
AQ
04/12ELI LILLY AND : Lilly Announces CYRAMZA® ramucirumab Phase 3 REACH-2 Study in Se..
AQ
04/12ELI LILLY AND : Lilly and Sigilon Therapeutics Announce Strategic Collaboration ..
AQ
04/10ELI LILLY AND : Ensuring Pay Equity for All Employees
PU
04/09ELI LILLY AND : Health and Human Services Department (HHS); Food and Drug Admini..
AQ
More news
News from SeekingAlpha
08:28aEli Lilly and Incyte down premarket ahead on bearish outlook on Ad Com review.. 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/17Evelo Biosciences Files For U.S. IPO 
04/172 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025 
04/16vTv Therapeutics Fails Late-Stage Alzheimer's Study; Is There A Chance For A .. 
Financials ($)
Sales 2018 23 369 M
EBIT 2018 6 129 M
Net income 2018 4 748 M
Debt 2018 5 405 M
Yield 2018 2,90%
P/E ratio 2018 18,13
P/E ratio 2019 16,20
EV / Sales 2018 3,96x
EV / Sales 2019 3,83x
Capitalization 87 110 M
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 90,9 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Jan M. Lundberg Executive Vice President-Science & Technology
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY-5.38%87 110
JOHNSON & JOHNSON-6.57%342 627
PFIZER0.86%217 064
NOVARTIS-4.37%213 465
ROCHE HOLDING LTD.-12.13%193 887
MERCK AND COMPANY4.71%158 813